human
enteroviru
caus
agent
hand
foot
mouth
diseas
hfmd
becom
seriou
health
threat
young
children
asia
pacif
region
last
year
although
hfmd
commonli
caus
member
coxsackieviru
famili
genet
relat
infect
often
associ
neurolog
complic
children
year
age
respons
major
fatal
major
concern
emerg
syndrom
rapidli
fatal
pulmonari
edema
associ
brainstem
enceph
asian
epidem
outbreak
hfmd
china
half
million
case
report
among
children
result
fatal
case
primarili
due
infect
recent
outbreak
cambodia
led
death
children
year
age
sampl
obtain
fatal
case
test
posit
sinc
nearli
complet
erad
polio
regard
preemin
neurotroph
viru
threat
global
public
health
date
specif
antivir
vaccin
clinic
use
prevent
mainli
achiev
disrupt
viru
transmiss
improv
public
hygien
kindergarten
preschool
daycar
center
aid
temporari
closur
affect
place
number
anim
studi
shown
neutral
antibodi
stimul
immun
inactiv
viru
vlp
display
crossprotect
heterolog
strain
passiv
protect
mice
monkey
studi
patient
indic
infect
clear
humor
immun
clinic
trial
shown
presenc
neutral
antibodi
serum
immun
healthi
adult
children
signific
involv
neutral
antibodi
respons
control
infect
human
would
render
ivig
treatment
ideal
therapeut
agent
complement
vaccin
passiv
immun
ivig
pool
sera
convalesc
human
donor
pioneer
behr
kitasato
develop
antidiphtheria
serum
howev
besid
risk
transmit
human
pathogen
use
pool
human
sera
necessit
screen
treatment
disadvantag
ie
avail
donor
batch
batch
variabl
presenc
serum
viru
specif
nonneutr
antibodi
solut
would
exploit
futur
passiv
immunotherapi
base
monoclon
antibodi
mab
produc
cell
cultur
small
nonenvelop
singl
positivestrand
rna
viru
belong
picornavirida
famili
genu
enteroviru
speci
enteroviru
nake
genom
enclos
icosahedr
capsid
compos
four
structur
protein
form
surfac
virion
arrang
intern
rapid
mutat
rate
rna
virus
result
emerg
new
subgenogroup
everi
year
date
subgenogroup
identifi
base
capsid
protein
variabl
four
three
genogroup
denot
b
c
b
c
divid
subgenogroup
cocircul
differ
genogroup
emerg
novel
strain
observ
asian
pandem
interestingli
shown
genotyp
correspond
viru
strain
antigen
point
presenc
conform
epitop
independ
sequenc
homolog
surpris
univers
neutral
epitop
describ
thu
far
ie
linear
epitop
encompass
amino
acid
region
conserv
among
subtyp
make
univers
neutral
epitop
monoclon
antibodi
epitop
abl
protect
mous
pup
lethal
infect
given
picornavirus
polioviru
carri
multipl
neutral
epitop
includ
conform
epitop
expect
also
possess
one
linear
neutral
epitop
inde
case
report
isol
first
conform
univers
neutral
mab
anim
experi
carri
accord
guidelin
anim
experi
nation
advisori
committe
laboratori
anim
research
naclar
experiment
protocol
review
approv
institut
anim
care
use
committe
temasek
life
scienc
laboratori
nation
univers
singapor
singapor
iacuc
approv
number
african
green
monkey
cell
line
vero
atcc
number
rhabdomyosarcoma
cell
line
rd
atcc
number
obtain
american
type
cultur
collect
atcc
grown
dulbecco
modifi
eagl
medium
dmem
gibco
usa
contain
fetal
bovin
serum
fb
biowest
franc
wildtyp
wt
strain
strain
obtain
host
pathogen
interact
laboratori
depart
microbiolog
yong
loo
lin
school
medicin
nation
univers
singapor
genbank
access
number
repres
subgenogroup
list
tabl
miss
subgenogroup
genbank
genbank
genbank
construct
use
human
rna
polymeras
revers
genet
system
insert
relev
gene
backbon
strain
genbank
virus
propag
rd
cell
cultur
supplement
fb
cell
cultur
supernat
harvest
day
post
infect
dpi
cytopath
effect
cpe
observ
three
freezethaw
cycl
filtrat
um
cutoff
filter
sartoriu
germani
aliquot
store
viru
activ
test
rd
cell
endpoint
dilut
assay
determin
tissu
cultur
infect
dose
anim
immun
inactiv
binari
ethylenimin
bei
h
describ
bahnemann
viru
concentr
ultracentrifug
g
h
resuspend
pb
three
specif
pathogenfre
balbc
mice
immun
subcutan
day
inactiv
strain
ml
pb
emulsifi
equal
volum
adjuv
seppic
franc
intraperiton
booster
viru
dose
without
adjuv
administ
day
mice
euthan
spleen
cell
harvest
splenocyt
fuse
myeloma
cell
describ
result
hybridoma
grown
dmem
fb
contain
hat
ht
day
hybridoma
screen
ifa
vero
cell
infect
cell
secret
specif
antibodi
subclon
limit
dilut
cultur
vero
african
green
monkey
kidney
cell
infect
use
antibodi
screen
cell
seed
overnight
well
microtit
plate
infect
dilut
next
morn
upon
observ
cpe
cell
fix
paraformaldehyd
ph
min
permeabil
tritonxpb
min
cell
block
pb
contain
fb
h
rt
incub
overnight
hybridoma
cell
supernat
mab
posit
control
antimous
fitccoupl
secondari
antibodi
ad
h
rt
ell
wash
three
time
pbstween
step
result
document
invert
microscop
olympu
nikon
softwar
ifa
escap
mutant
rg
virus
conduct
infect
rd
cell
use
protocol
reversegenet
rg
construct
virus
propag
rd
cell
cultur
harvest
supernat
purifi
sucros
gradient
centrifug
cell
pellet
centrifug
g
min
supernat
ultracentrifug
g
h
result
pellet
resuspend
centrifug
discontinu
sucros
gradient
g
h
viru
band
collect
concentr
viru
pb
ad
sucros
gradient
band
centrifug
g
h
resuspend
pb
protein
concentr
measur
nanodrop
purifi
virus
dilut
mgml
rg
virus
mix
sd
boil
min
dilut
time
around
viru
dot
nitrocellulos
membran
blot
block
milk
pb
h
rt
incub
primari
antibodi
h
rt
wash
pbst
blot
incub
antimous
secondari
antibodi
ecl
reagent
ge
healthcar
usa
imag
captur
chemidoc
mp
imag
system
biorad
laboratori
inc
usa
neutral
titer
mab
hybridoma
cell
cultur
supernat
measur
vitro
microneutr
assay
use
rd
cell
wildtyp
escap
mutant
rg
virus
mix
equal
amount
serial
dilut
mab
mab
posit
control
mixtur
incub
h
rt
ad
triplic
well
microtit
plate
contain
confluent
rd
cell
presenc
cpe
determin
day
examin
light
microscop
highest
dilut
mab
inhibit
viru
growth
consid
neutral
titer
express
assay
carri
independ
three
time
wildtyp
viru
stock
dilut
titer
accordingli
viru
incub
equal
volum
neat
mab
hybridoma
supernat
h
room
temperatur
rt
mixtur
transfer
confluent
rd
cell
dmem
fb
incub
day
cpe
observ
supernat
harvest
subject
three
freezethaw
cycl
filter
um
cutoff
reinfect
fresh
batch
rd
cell
day
repeat
cpe
observ
reinfect
cycl
need
cpe
henc
escap
mutant
develop
escap
mutant
call
three
individu
experi
use
viru
two
individu
experi
use
strain
ea
measur
end
point
dilut
ifa
well
microneutr
mab
conduct
confirm
abolish
antibodi
bind
neutral
viral
rna
isol
kit
qiagen
germani
use
extract
viral
rna
filter
rd
cell
cultur
supernat
contain
wildtyp
escap
mutant
viru
typic
yield
measur
nanodrop
thermofish
scientif
usa
revers
transcript
carri
ng
rna
use
gene
strainspecif
primer
togeth
amv
revers
transcriptas
roch
appli
scienc
germani
accord
manufactur
protocol
pcr
amplif
overlap
portion
region
conduct
use
primer
pair
tabl
high
fidel
pcr
system
roch
appli
scienc
germani
cycl
paramet
follow
denatur
min
follow
cycl
denatur
sec
touchdown
anneal
decrement
sec
extens
min
follow
cycl
denatur
sec
anneal
sec
extens
sec
per
cycl
increment
final
extens
min
result
pcr
product
analyz
agaros
gel
purifi
qiaquick
gel
extract
kit
qiagen
germani
direct
sequenc
reaction
perform
use
gene
strainspecif
primer
bigdy
termin
cycl
dnaoligonucleotid
synthesi
core
temasek
life
scienc
laboratori
singapor
sequenc
analyz
use
lasergen
program
dnastar
usa
genom
wild
type
viru
first
amplifi
rtpcr
subject
human
rna
polymeras
promot
describ
previou
paper
infecti
plasmid
contain
cdna
sequenc
confirm
authent
transfect
rd
cell
gener
viru
mutat
introduc
plasmid
sitedirect
mutagenesi
stratagen
usa
use
primer
tabl
doubl
mutat
mutat
primer
correct
mutat
plasmid
transfect
rd
cell
gener
mutant
design
respect
anim
experi
conduct
two
week
old
mice
mice
obtain
b
k
univers
uk
hous
bred
specif
pathogenfre
condit
individu
ventil
cage
test
protect
efficaci
antibodi
mice
randomli
divid
two
group
mice
group
mice
prophylact
group
inject
intraperiton
purifi
mab
antibodi
ml
glycerol
dissolv
pb
concentr
mgg
bodi
weight
day
one
group
mice
isotyp
control
group
given
equal
amount
purifi
mous
igm
isotyp
control
ebiosci
usa
two
group
mice
subject
lethal
challeng
plaqu
form
unit
pfu
strain
hfm
via
intraperiton
rout
ml
pb
h
postinject
immunoglobulin
surviv
rate
clinic
score
mice
monitor
daili
till
day
postinfect
total
limb
paralysi
use
criterion
earli
euthanasia
brain
sampl
collect
fix
formalin
embed
paraffin
block
cut
mm
thick
leica
microsystem
germani
attach
coat
glass
slide
slide
stain
hematoxylin
eosin
h
e
observ
light
microscopi
discov
novel
neutral
epitop
three
balbc
mice
immun
inactiv
strain
viru
emuls
adjuv
seppic
franc
strain
propag
rd
cell
supernat
contain
viru
inactiv
bei
concentr
ultracentrifug
prior
immun
booster
administ
day
interv
sera
test
day
later
presenc
antibodi
ifa
vero
cell
sera
exhibit
posit
ifa
signal
intraperiton
booster
administ
without
adjuv
spleen
harvest
three
day
later
splenocyt
fuse
myeloma
cell
result
hybridoma
cultur
select
medium
supernat
screen
ifa
vero
cell
posit
hybridoma
subclon
limit
dilut
supernat
analyz
presenc
neutral
antibodi
screen
sever
mab
isol
character
focus
attent
mab
sinc
mab
react
posit
subgenogroup
ifa
crossreact
fig
promis
featur
mab
could
potenti
appli
differenti
diagnosi
hfmd
distinguish
cva
infect
secondli
mab
abl
neutral
subgenogroup
neutral
titer
genogroup
b
genogroup
c
wildtyp
viru
tabl
use
hybridoma
cell
supernat
univers
neutral
abil
make
mab
ideal
candid
diagnosi
treatment
infect
sinc
western
blot
analysi
whole
viru
overlap
polyprotein
fragment
tag
gst
result
band
mab
investig
reactiv
mab
nativ
denatur
virus
dot
blot
assay
although
mab
react
revers
genet
engin
wildtyp
viru
blot
nativ
form
nativ
recogn
viru
denatur
boil
sd
denatur
fig
mab
recogn
linear
epitop
use
posit
control
could
inde
react
nativ
denatur
virus
conclus
mab
recogn
conform
epitop
final
mab
immunoglobulin
isotyp
determin
igm
use
mous
monoclon
antibodi
isotyp
kit
santa
cruz
biotechnolog
inc
usa
epitop
mab
found
conform
sinc
mab
react
capsid
protein
western
blot
henc
epitop
could
map
convent
fashion
truncat
peptid
therefor
epitop
map
mab
perform
escap
mutant
select
wildtyp
virus
differ
subgenogroup
incub
excess
mab
rd
cell
cpe
visibl
day
supernat
filter
ad
fresh
rd
cell
process
repeat
cpe
evid
cycl
necessari
isol
escap
mutant
subgenogroup
escap
mutant
design
ea
two
experi
use
viru
three
individu
experi
use
viru
measur
endpoint
dilut
assay
test
reactiv
mab
ifa
rd
cell
infect
equal
amount
either
wildtyp
viru
posit
control
escap
virus
observ
day
cpe
visibl
fig
incub
mab
clear
fluoresc
signal
wildtyp
virus
fig
signal
detect
correspond
escap
mutant
fig
confirm
escap
mutant
evad
mab
bind
microneutr
assay
escap
virus
conduct
viru
neutral
mab
identifi
escap
mutant
howev
neutral
mab
recogn
unalt
epitop
abl
neutral
escap
mutant
tabl
delin
amino
acid
mutat
associ
neutral
escap
differ
subgenogroup
structur
gene
region
escap
mutant
sequenc
compar
parent
strain
eight
escap
mutant
four
mutat
identifi
structur
gene
mutant
deriv
parent
strain
harbor
glutam
aspart
substitut
amino
acid
posit
three
mutant
ea
deriv
subgenogroup
carri
prolin
leucin
substitut
amino
acid
posit
two
separ
mutat
discov
amino
acid
escap
mutant
strain
alanin
aspart
acid
prolin
tabl
sinc
discov
singl
amino
acid
mutat
capsid
protein
escap
mutant
infer
residu
essenti
mab
bind
viru
neutral
test
hypothesi
engin
viru
consist
sequenc
util
human
rna
polymeras
driven
revers
genet
system
four
mutat
introduc
alon
tandem
wildtyp
rg
viru
rgv
sitedirect
mutagenesi
rg
virus
rescu
rd
cell
passag
virus
use
subsequ
experi
bind
abil
mab
repres
mutat
rg
virus
first
test
ifa
fig
dot
blot
fig
rd
cell
infect
viru
posit
control
mutat
rg
virus
cell
fix
dpi
cpe
clearli
observ
fig
origin
viru
clearli
detect
mab
fluoresc
visibl
mutat
rgv
carri
either
singl
doubl
mutat
addit
mab
unabl
neutral
mutat
rg
virus
vitro
microneutr
assay
neutral
titer
mab
reach
tabl
posit
control
mab
linear
neutral
epitop
kqekd
incub
mutat
rg
virus
sinc
epitop
unaffect
mutagenesi
mab
still
abl
effici
neutral
rg
virus
fig
henc
demonstr
four
escap
mutat
suffici
abolish
mab
bind
protein
neutral
viru
identifi
amino
acid
essenti
mab
bind
neutral
next
investig
whether
residu
conserv
fulli
sequenc
strain
avail
genbank
blast
analysi
amino
acid
reveal
total
hit
ident
region
analyz
amino
acid
ident
full
protein
thu
highli
conserv
subgenogroup
ident
make
ideal
target
diagnost
therapeut
mab
region
also
compar
strain
exhibit
sequenc
homolog
tabl
view
recent
avail
crystal
structur
epitop
mab
could
locat
stereograph
imag
analyz
locat
epitop
relat
previous
identifi
epitop
linear
neutral
epitop
kqekd
mab
linear
epitop
edshp
mab
studi
stereograph
imag
protom
fig
epitop
mab
shown
viru
surfac
fig
protein
shown
escap
mutat
indic
site
lie
major
protrus
capsid
surfac
term
knob
fig
protom
consist
one
copi
viral
capsid
protein
pink
blue
brown
green
shown
top
imag
correspond
surfac
virion
bottom
locat
insid
two
orient
shown
b
major
groov
form
visibl
right
foreground
back
c
imag
rotat
display
posit
escap
mutat
clearli
foreground
back
indic
yellow
epitop
previous
identifi
mab
well
conform
neutral
epitop
mab
knob
region
arrow
three
escap
mutat
site
amino
acid
posit
indic
shown
fig
conform
chang
gener
escap
mutant
follow
loss
cyclic
structur
prolin
side
chain
mutant
addit
cyclic
side
chain
mutant
carboxyl
group
mutant
loss
methylen
bridg
mutant
test
protect
efficaci
mab
two
week
old
mice
inject
intraperiton
purifi
mab
isotyp
control
mab
one
day
later
challeng
lethal
dose
virul
strain
clinic
score
well
surviv
rate
mice
monitor
daili
control
anim
receiv
isotyp
antibodi
develop
sever
limb
paralysi
earli
day
postinfect
contrast
mice
pretreat
mab
display
diseas
manifest
remain
healthi
throughout
experi
result
thu
suggest
antibodi
mab
administ
dose
mgg
bodi
weight
abl
achiev
protect
lethal
challeng
confirm
protect
efficaci
mab
histopatholog
examin
mous
brain
conduct
mice
isotyp
control
group
exhibit
neuron
vacuol
neuron
loss
without
inflamm
brain
stem
fig
contrast
observ
patholog
chang
mice
prophylact
group
treat
intact
brain
morpholog
fig
suggest
mab
capabl
confer
vivo
passiv
protect
infect
despit
evid
enterovirus
major
conform
neutral
site
capsid
protein
date
map
univers
neutral
epitop
linear
epitop
span
amino
acid
wherea
known
conform
epitop
strainspecif
includ
amino
acid
order
find
optim
mab
futur
use
immunolog
therapeut
either
alon
conjunct
mab
larger
pool
univers
neutral
mab
candid
would
desir
therefor
undertook
task
isol
mab
deriv
mice
immun
strain
select
virul
consist
attain
higher
cell
cultur
abl
caus
diseas
older
mice
pup
strain
test
unpublish
observ
strain
isol
fatal
case
hfmd
enceph
singapor
outbreak
found
mab
effici
neutral
subgenogroup
without
crossreact
make
highli
specif
antibodi
potenti
applic
differenti
diagnosi
hfmd
sinc
epitop
found
conform
crucial
gener
escap
mutant
order
map
exact
epitop
mutat
amino
acid
prolin
leucin
posit
alanin
aspart
acid
prolin
posit
glutam
aspart
posit
result
escap
mab
bind
neutral
residu
integr
knob
structur
protein
protrud
capsid
surfac
complet
conserv
among
sequenc
deposit
genbank
henc
discov
addit
conform
epitop
provid
first
evid
anoth
capsid
protein
involv
viru
neutral
besid
knob
encompass
residu
make
longer
knob
describ
coxsackieviru
contain
major
neutral
site
picornavirus
polioviru
human
rhinoviru
hepat
viru
hepat
viru
immunodomin
epitop
involv
residu
close
mutat
identifi
screen
situat
complex
polioviru
nagi
major
neutral
epitop
serotyp
sabin
nagii
nagiii
immunodomin
mahoney
howev
neutral
iga
mab
deriv
immun
mice
predominantli
direct
nagiii
epitop
form
amino
acid
map
onto
viru
structur
residu
close
proxim
knob
pass
right
front
fig
pink
tube
upper
right
protom
structur
remain
seen
escap
mutant
might
also
alter
cterminu
addit
knob
residu
may
contribut
epitop
format
escap
mutant
anoth
enteroviru
coxsackieviru
harbor
mutat
knob
puff
mutat
map
residu
mutat
locat
residu
stereograph
imag
reveal
two
mutat
lie
close
proxim
one
anoth
form
conform
epitop
analog
close
analyz
identifi
epitop
sinc
previous
identifi
nonneutr
linear
mab
linear
epitop
quit
close
ie
residu
investig
whether
amino
acid
might
involv
form
conform
epitop
well
readili
deduc
stereograph
imag
puff
resid
much
away
knob
neither
residu
close
proxim
identifi
escap
mutat
instead
epitop
adjac
neutral
epitop
indic
two
linear
epitop
may
interact
could
explain
low
neutral
activ
observ
commerci
avail
merck
millipor
germani
recogn
peptid
span
residu
encompass
epitop
neutral
monoclon
antibodi
specif
antivir
agent
use
passiv
immun
patient
acut
viral
infect
offer
select
advantag
pool
human
sera
commonli
use
ivig
treatment
reduc
risk
transmit
pathogen
allevi
batchtobatch
variabl
avail
donor
presenc
nonneutr
antibodi
sever
factor
consid
use
mab
instead
polyclon
serum
ivig
includ
antigen
variabl
circul
strain
ie
mab
must
crossneutr
exist
subtyp
use
b
risk
escap
mutat
eg
mutant
may
emerg
select
pressur
presenc
neutral
antibodi
circumv
risk
cocktail
two
antivir
mab
nonoverlap
epitop
administ
escap
mutat
singl
mab
interfer
neutral
capabl
second
mab
combin
synergist
mab
may
also
reduc
requir
dosag
conclus
protect
efficaci
mab
evalu
verifi
anim
challeng
experi
use
lethal
dose
mice
prophylact
treat
mab
surviv
lethal
challeng
without
show
diseas
symptom
henc
mab
hold
promis
develop
prophylact
agent
hfmd
